You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Relapsed Diffuse large B-cell lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Diffuse Large B Cell Lymphoma, Relapsed DLBCL, Refractory DLBCL Trial in Boston (Copanlisib, Venetoclax)

Active, not recruiting
  • Diffuse Large B Cell Lymphoma
  • +2 more
  • Duarte, California
  • +2 more
Nov 10, 2022

Relapsed Diffuse Large B-cell Lymphoma Trial in Detroit (loncastuximab tesirine)

Recruiting
  • Relapsed Diffuse Large B-cell Lymphoma
  • loncastuximab tesirine
  • Detroit, Michigan
    Barbara Ann Karmanos Cancer Institute
Jun 24, 2022

Relapsed or Refractory Diffuse Large B-cell Lymphoma Trial in Beijing (BEBT-908 for injection)

Active, not recruiting
  • Relapsed or Refractory Diffuse Large B-cell Lymphoma
  • BEBT-908 for injection
  • Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Oct 8, 2023

Diffuse Large B Cell Lymphoma | DLBCL Recurrent/Refractory Trial (ZR2-ICE)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Recurrent/Refractory
  • (no location specified)
Sep 5, 2023

Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory Trial in Hangzhou (Anlotinib HCl, Rituximab,

Recruiting
  • Diffuse Large B-cell Lymphoma Recurrent
  • Diffuse Large B Cell Lymphoma Refractory
  • Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Oct 12, 2023

Relapsed DLBCL, Refractory DLBCL Trial in Hackensack (ABT-199, Ibrutinib, Rituximab)

Active, not recruiting
  • Relapsed Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Hackensack, New Jersey
    John Theurer Cancer Center at Hackensack University Medical Cent
Oct 7, 2022

Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib, Polatuzumab vedotin and Rituximab)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Zanubrutinib, Polatuzumab vedotin and Rituximab
  • Shanghai, Shanghai, China
    Zhongshan Hospital，Fudan University
Jul 10, 2023

Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma Trial in Beijing (Ociperlimab, Tislelizumab,

Recruiting
  • Relapsed Diffuse Large B-cell Lymphoma
  • Refractory Diffuse Large B-cell Lymphoma
  • Beijing, Beijing, China
    Beijing Cancer Hospital
May 4, 2022

DLBCL Trial in Jinan (Mitoxantrone Hydrochloride Liposome Injection)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • Mitoxantrone Hydrochloride Liposome Injection
  • Jinan, Shandong, China
    Affiliated Cancer Hospital of Shandong First Medical University
May 16, 2023

DLBCL Trial in China (Orelabrutinib and Gemox)

Not yet recruiting
  • DLBCL
  • Orelabrutinib and Gemox
  • Chongqing, Chongqing, China
  • +7 more
Jul 5, 2022

Relapsed DLBCL, Refractory DLBCL Trial in New York (Ipilimumab, Nivolumab)

Completed
  • Relapsed Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Apr 4, 2022

Recurrent DLBCL, Refractory Diffuse Large B-cell Lymphoma Trial in Tianjin (RC19D2 cell injection)

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-cell Lymphoma
  • RC19D2 cell injection
  • Tianjin, Tianjin, China
    Hematology Hospital of the Chinese Academy of Medical Sciences
Sep 14, 2023

Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Isophosphamide)

Not yet recruiting
  • Diffuse Large B-cell Lymphoma
  • (no location specified)
Mar 23, 2023

Relapsed/Refractory Diffuse Large B Cell Lymphoma Trial in Seoul (Glofitamab, Poseltinib, Lenalidomide)

Recruiting
  • Relapsed/Refractory Diffuse Large B Cell Lymphoma
  • Glofitamab, Poseltinib, Lenalidomide
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Nov 28, 2022

Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Diffuse Large B Cell Lymphoma
  • CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital
Nov 19, 2023

DLBCL, High-grade B-cell Lymphoma Trial (Loncastuximab Tesirine)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • High-grade B-cell Lymphoma
  • Loncastuximab Tesirine
  • (no location specified)
Dec 13, 2022

Non-hodgkin Lymphoma,B Cell, Refractory DLBCL, Relapsed DLBCL Trial in United States (MT-3724, Gemcitabine, Oxaliplatin)

Terminated
Has Results
  • Non-hodgkin Lymphoma,B Cell
  • +2 more
  • Orange, California
  • +8 more
Jul 18, 2022

Chidamide in Recurrent and Refractory Diffuse Large b

Enrolling by invitation
  • Diffuse Large B-cell Lymphoma
  • Suzhou, Jiangsu, China
    Second Affiliated Hospital of Soochow University
Jan 9, 2023

DLBCL Trial (maplirpacept (PF-07901801), Glofitamab, Obinutuzumab)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • maplirpacept (PF-07901801)
  • +2 more
  • (no location specified)
May 30, 2023

B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • CD19/CD22-bispecific CAR-T cells
  • Beijing, Beijing, China
    Liang Wang
Oct 7, 2023

Diffuse Large B Cell Lymphoma Trial (Pembrolizumab, Rituximab, Ifosfamide)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Headington, Oxford, United Kingdom
  • +1 more
Nov 2, 2022

Lymphoma, B-Cell, Relapsed Cancer, Refractory Lymphoma Trial in Boston (Adaptive Bridging Radiation Therapy (ABRT))

Not yet recruiting
  • Lymphoma, B-Cell
  • +7 more
  • Adaptive Bridging Radiation Therapy (ABRT)
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Aug 16, 2023

Diffuse Large B Cell Lymphoma Trial (anti-CD19 CAR NK cells)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • anti-CD19 CAR NK cells
  • (no location specified)
Dec 21, 2022

Large Cell Lymphoma, Diffuse, Relapsed Cancer, Refractory Cancer Trial (AutoSCT, GDP, Epcoritamab)

Not yet recruiting
  • Large Cell Lymphoma, Diffuse
  • +2 more
  • AutoSCT
  • +2 more
  • (no location specified)
May 10, 2023

DLBCL Trial in San Juan (PF-07901801, Tafasitamab, Lenalidomide)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • San Juan, Puerto Rico
    Auxilio Mutuo Cancer Center
Jan 19, 2023